Family offices, holdings, direct investors in unlisted companies

Objectify the resilience of an unlisted company.

The large data providers cover listed companies. For an unlisted SME, no accessible standard exists. Archimede produces one, from the data room.

01 · Your situation

What we hear most often

01

The blind spot

Bloomberg, MSCI, Sustainalytics: those frameworks cover listed companies. Your target is an unlisted SME, and none of it applies.

02

One-off due diligence

A consultant produces an analysis for one deal — expensive, one-off, and leaving nothing comparable for the next holding.

03

Reporting expectations

The family or the partners ask for a resilience section. You have nothing standardised to show across a portfolio.

04

The calendar

A full due diligence does not fit inside the time it takes to make an investment decision, or to reinvest.

Unlisted companies are the blind spot of the large data providers. Score your targets on a single grid.
02 · What changes

Four concrete differences

What changes · 01

One grid for the whole portfolio

The same reading for every holding, so companies finally become comparable with each other — and their progress can be tracked over time.

What changes · 02

Data already in place

Accounts, supply, energy: what a data room already contains is enough. Seven figures, all already there.

What changes · 03

Complementary, not a substitute

Your financial and legal due diligence remains yours. Archimede adds the resilience axis; it replaces nothing.

What changes · 04

A diagnostic, not a label

Archimede issues no regulatory recognition and no external validation. It is a reading instrument, nothing more.

03 · What you do with it

From reading to decision

A screen before you invest

See where a target is fragile before signing, on dimensions the accounts alone do not show.

Compare what was not comparable

Place holdings from different sectors side by side, thanks to a reading expressed as risk rather than in raw units.

Track over time

Repeat the measurement each year and see whether the situation is deteriorating or improving — a follow-up, not a report filed in a drawer.

Feed your reporting

Hold a standardised element to present to the family or to partners, without claiming a compliance we do not deliver.

04 · Who this is not for

We would rather say so first

  • Your portfolio is listed: listed companies are not our ground, other tools cover them better than we do.
  • You do not invest directly, but allocate to funds: we are not the right tool.
  • You are looking for a label or a recognised standard: Archimede is a diagnostic and issues no recognition.
05 · Questions

The objections that keep coming back

Our portfolio is listed.

Then you are not the target: the large data providers do that job better than we do. Unlisted companies are our ground.

It is not a recognised standard.

Correct, and we do not present it as one. It is a diagnostic that complements your internal grid; it does not replace it and claims no external recognition.

The price.

€200 per month, or €1,000 for five organisations and €2,000 for twelve. Compare that with the tens of thousands of euros a year spent on listed-company ESG data — which does not cover your target anyway.

We trust the management team.

That is a defensible position. Archimede exists precisely to test it on the dimensions where intuition is most often wrong: supply tension and revenue sensitivity.

06 · Plans

What it costs

Portfolio

€1,000 / month

Five organisations, so five holdings.

  • The same grid for every target
  • Portfolio comparability
  • Year-on-year tracking
  • Twelve organisations: €2,000
Request a demo
Large accounts

Contact us

Unlimited organisations.

  • Unlimited organisations
  • API connection to your tools
  • Introductions to specialists
  • Dedicated support
Request a demo

Annual commitment: 20 % off. Transition players: privileged access until the end of 2026 by joining our testing programmes.

Already in use

A wealth manager uses Archimede to inform client investment decisions on unlisted targets.

We score one existing holding from your portfolio as a test, and show you the comparability it produces.

One session of about an hour, seven figures from your accounts, and you leave with your compass.